Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review

December 2021 | 41 pages | ID: D1AF3A23671EN
GlobalData

Abstracts

Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Daxor Corp (Daxor) is a biotechnology company, which offers original medical equipment for medical personnel. The company manufactures blood volume analyzers. Its flagship product, BVA-100 blood volume analyzer is an instrument to measure human blood volume. The product is used in conjunction with Volumex, a diagnostic radiopharmaceutical containing iodinated I 131 albumins. It finds application in a range of medical and surgical conditions which includes congestive heart failure, intensive care unit medicine, critical care medicine, syncope, hypertension, kidney failure, renal failure, red blood cell abnormalities, hyponatremia and other conditions. The company offers its product to hospitals, clinics and physicians. Daxor is headquartered in Oak Ridge, the US.

Daxor Corp Key Recent Developments

Sep 07,2021: Daxor to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
Jun 30,2021: Daxor reports a 26.5 percent rise in diagnostic sales revenue in form N-CSR filing for the six months ended June 30, 2021
May 28,2021: Daxor to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021
May 13,2021: Daxor Announces 61% Increase in Q1 2021 Sales Revenue
Mar 04,2021: Daxor to Present at the H.C. Wainwright Global Life Sciences Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Daxor Corp - Key Facts
Daxor Corp - Key Employees
Daxor Corp - Key Employee Biographies
Daxor Corp - Major Products and Services
Daxor Corp - History
Daxor Corp - Company Statement
Daxor Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Daxor Corp - Business Description
Daxor Corp - SWOT Analysis
SWOT Analysis - Overview
Daxor Corp - Strengths
Daxor Corp - Weaknesses
Daxor Corp - Opportunities
Daxor Corp - Threats
Daxor Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Daxor Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
Daxor Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
Daxor Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 07, 2021: Daxor to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
Jun 30, 2021: Daxor reports a 26.5 percent rise in diagnostic sales revenue in form N-CSR filing for the six months ended June 30, 2021
May 28, 2021: Daxor to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021
May 13, 2021: Daxor Announces 61% Increase in Q1 2021 Sales Revenue
Mar 04, 2021: Daxor to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 26, 2021: Daxor Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020
Mar 02, 2020: Daxor announces engagement with hospitals and government for use of the Blood Volume Analyzer (BVA-100) to stem COVID-19 deaths
Mar 02, 2020: Daxor announces rise in kit sales and files form N-CSR for 2019

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Daxor Corp, Key Facts
Daxor Corp, Key Employees
Daxor Corp, Key Employee Biographies
Daxor Corp, Major Products and Services
Daxor Corp, History
Daxor Corp, Subsidiaries
Daxor Corp, Key Competitors
Daxor Corp, Annual Ratios
Daxor Corp, Annual Ratios (Cont...1)
Daxor Corp, Interim Ratios
Daxor Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
Daxor Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
Daxor Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Daxor Corp, Performance Chart (2016 - 2020)
Daxor Corp, Ratio Charts
Daxor Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
Daxor Corp, Medical Equipment, Deals by Type, 2015 to YTD 2021